Repare Therapeutics Inc.
General ticker "RPTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $67.1M (TTM average)
Repare Therapeutics Inc. follows the US Stock Market performance with the rate: 30.6%.
Estimated limits based on current volatility of 2.2%: low 2.12$, high 2.20$
Factors to consider:
- Total employees count: 129 (-27.9%) as of 2024
- US accounted for 4.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Insufficient funding, High development costs, Regulatory and compliance, Challenges in patient enrollment, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.26$, 3.67$]
- 2025-12-31 to 2026-12-31 estimated range: [1.55$, 4.18$]
Financial Metrics affecting the RPTX estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -137.83 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 89.19 > -0.66
- Positive: Shareholder equity ratio, % of 85.62 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term RPTX quotes
Long-term RPTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $131.83MM | $51.13MM | $53.48MM |
| Operating Expenses | $151.63MM | $167.36MM | $147.00MM |
| Operating Income | $-19.80MM | $-116.22MM | $-93.52MM |
| Non-Operating Income | $5.90MM | $13.04MM | $10.27MM |
| R&D Expense | $119.07MM | $133.59MM | $115.94MM |
| Income(Loss) | $-13.90MM | $-103.18MM | $-83.25MM |
| Taxes | $15.15MM | $-9.38MM | $1.44MM |
| Profit(Loss)* | $-29.05MM | $-93.80MM | $-84.69MM |
| Stockholders Equity | $279.52MM | $212.08MM | $151.13MM |
| Assets | $364.07MM | $253.90MM | $176.51MM |
| Operating Cash Flow | $0.32MM | $-127.16MM | $-76.44MM |
| Capital expenditure | $0.60MM | $1.94MM | $0.00MM |
| Investing Cash Flow | $-175.78MM | $78.04MM | $49.47MM |
| Financing Cash Flow | $0.88MM | $0.84MM | $0.54MM |
| Earnings Per Share** | $-0.69 | $-2.23 | $-2.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.